PPARG and fatty liver disease: In conclusion, this study showed that genetic or pharmacological inhibition of PTGR2 prevented diet-induced obesity, reduced insulin resistance, and decreased hepatic steatosis via increasing endogenous PPARγ ligands without adverse side effects such as fluid retention and osteoporosis.